肿瘤干细胞标志物CD133在乳腺癌组织中的表达及其临床意义

Expression and Significance of CD133 in Breast Cancer

目的探讨肿瘤干细胞标志物CD133在乳腺癌组织中的表达及其临床意义。方法采用免疫组织化学方法检测109例乳腺癌组织和60例乳腺良性肿瘤组织中CD133的表达,分析其与乳腺癌亚型及临床病理参数间的关系。结果109例乳腺癌组织中,CD133表达的阳性率为46.8%(51/109),60例乳腺良性肿瘤的阳性率为0.33%(2/60),两者差异具有高度统计学意义(P<0.01);109例乳腺癌组织中,CD133蛋白的表达随病理级别的增加而升高(P<0.05),随临床分期升高及肿瘤直径增大呈下降趋势(P>0.05);乳腺癌4种亚群中,Basal-like亚群中CD133蛋白的阳性率最高,为69.2%,显著高于其他亚群,差异有统计学意义(P<0.05)。结论早期低分化或未分化癌更富于干细胞,可能与肿瘤细胞恶性演进有关;CD133蛋白的表达具有区分不同乳腺癌亚型作用以及在乳腺癌的预后预测具有重要作用。

Objective To investigate the expression of CD133 protein in breast cancer and its re- lationship with the clinical characteristics of tumors. Methods In one hundred and nine cases of breast cancer CD133 tissues was detected by immunohistochemistry for CD133, and results were compared with those in 60 benign tumor tissues. Results The expression rate of CD133 protein were 46.8%（51/109） in 109 cases of breast cancer. It was much higher than that in benign tumor tissues samples which was 0.33%（2/60）. The difference was statistically significant （P〈0.01）. The expression of CD133 was related with tumor grade and subtypes（P〈0.05）. Conclusion The high expression of CD133 in breast cancer is closely related to the differentiation and subtypes of breast cancer. It can be used as an important factor in judging the prognosis of breast cancer.